Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens.
Chemotherapy of the larval stage of Echinococcus granulosus in man with high oral doses of mebendazole has only been partly successful. In order to improve effective pharmacotherapy of this disease with mebendazole, the optimal time for blood sampling has been assessed and the mebendazole concentrations acting on the parasite have been compared with their viability. The optimal time for blood sampling was analysed in 14 patients during longterm treatment with mebendazole. The plasma level 4 h after the morning dose exhibited the best correlation with the average 24-h concentration, suggesting that the plasma level should be monitored 4 h after the morning dose. In 22 patients undergoing surgery for hydatid disease, the mebendazole concentration in cyst fluid was significantly correlated with its plasma level 4 h after the morning dose. In 13 of them the free drug concentration was determined by equilibrium dialysis and it was almost identical with the free mebendazole concentration in plasma. Results of viability tests in 12 cases revealed viable cysts in 6 cases and possibly viable cysts in 6 other cases. Even patients treated for more than 12 months still had viable cysts.
D000328:Adult; D000818:Animals; D001562:Benzimidazoles / Q000627:therapeutic use*; D004443:Echinococcosis / Q000188:drug therapy*; D004446:Echinococcus / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008463:Mebendazole / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D011485:Protein Binding
D001562:Benzimidazoles; D008463:Mebendazole